Benserazide
As of the edition of 20 October 2026, Benserazide is a small molecule: marketed, first approved in 1973 (CH); acts on DDC.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1980
- Kind
- Small molecule
- Brand name
- Madopar
- First approved
- 27 June 1973 (CH)
- Approvals on record
- 10 in 4 regions
- Holder of the most recent approval
- Roche; 3 holders in all
- Registered trials
- 11, 0 stopped early
- Disease areas
- Nervous system; Mental health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Benserazide.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| DDC | Aromatic-L-amino-acid decarboxylase | P20711 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 4 | 4 | 0 | 0 |
| Phase 2 | 2 | 2 | 0 | 0 |
| Phase 3 | 3 | 3 | 0 | 0 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 11 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Roche | Applicant | 1973 to now |